Quantcast
Last updated on April 20, 2014 at 13:20 EDT

Latest Herpes zoster Stories

2009-01-12 05:00:00

CAMBRIDGE, Mass., Jan. 12 /PRNewswire/ -- Solace Pharmaceuticals, a private biotechnology company discovering and developing innovative treatments for pain, announced the initiation of a proof-of-concept clinical trial of SLC022 in patients with post-herpetic neuralgia (PHN). PHN, a painful complication of shingles, affects approximately 200,000 people a year in the US alone. The clinical trial is an international, multi-center, placebo-controlled study that will examine the effectiveness...

4ee1962faf06ebff598bd1f4b55e16c01
2008-09-11 13:34:29

Scientists looking for treatments to control the AIDS virus may find hope in a cheap drug traditionally used to treat herpes. Dr. Leonid Margolis of the National Institute of Child Health and Human Development, helped lead the study published in the journal Cell Host & Microbe. Researchers found that acyclovir can work against HIV, but only in tissues that are also infected with herpes. "If you suppress herpes, HIV also goes down," Margolis said. Other studies have shown that people who...

2008-09-10 09:00:48

Epiphany Biosciences has announced that a Phase IIb dose-ranging study to evaluate the safety, efficacy, and tolerability of the company's lead compound, valomaciclovir in patients with acute herpes zoster infection, will continue as originally designed following an interim analysis. In addition to the Phase IIb zoster study, valomaciclovir will also be studied in a separate Phase II clinical trial as a therapy in managing the most severe sequelae of a herpes-zoster infection, post-herpetic...

2008-09-09 09:00:00

SAN FRANCISCO, Sept. 9 /PRNewswire/ -- Epiphany Biosciences, Inc. today announced that a Phase 2b dose-ranging study to evaluate the safety, efficacy, and tolerability of the company's lead compound, valomaciclovir (EPB-348) in patients with acute herpes zoster infection (shingles), will continue as originally designed following an interim analysis. Fred Volinsky, MD, Epiphany's CEO said, "We are pleased with the progress of this clinical trial and look forward to the final data. If...

2008-09-03 00:00:24

U.S. researchers say chickenpox cases have fallen by up to 90 percent in some communities since the vaccine was introduced in 1995. The Centers for Disease Control and Prevention said the vaccine has reduced infections in every age group, including infants too young to be vaccinated but benefit from the reduced exposure to the virus, USA Today reported Tuesday. A CDC report, published in the journal Pediatrics, said the vaccine has reduced chickenpox-related deaths to just 15 each year....

2008-08-29 00:00:36

The alarming fact is that over half of all Americans have oral herpes and at least twenty percent (one out of five) suffer from genital herpes or herpes simplex 2 (HSV-2). Studies indicate that more than 500,000 new cases of genital herpes are diagnosed in the United States each year and an untold number go untreated. Combine these figures with the number of other sexually transmitted diseases (S.T.D.s), added to the number of urinary tract infections (U.T.I.s) contracted every year, and the...

2008-08-21 12:01:29

BioVex has announced that the UK Medicines and Healthcare products Regulatory Agency has accepted BioVex's clinical trial application to conduct a Phase I clinical study testing the safety and immunogenicity of its lead infectious disease candidate for genital herpes, ImmunoVEX HSV2. ImmunoVEX HSV2 is a novel live-attenuated vaccine which has been rationally designed to remove the genes that allow herpes virus to avoid the immune system. This should allow the immune system to recognize and...

2008-08-21 09:01:14

LONDON, August 21 /PRNewswire/ -- The medicated pain relief plaster, (Versatis) is now approved by the Scottish Medicines Consortium (SMC) for restricted use within NHS Scotland for patients suffering pain following shingles(1) http://www.scottishmedicines.org.uk/smc/5850.html. This reversal of the previous SMC decision (issued in February 2007) for Versatis (5% lidocaine medicated plaster) is based on significant new clinical and cost-effectiveness comparative data and brings prescribing...

2008-08-20 09:00:22

WOBURN, Mass., Aug. 20 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, today announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has accepted BioVex's Clinical Trial Application to conduct a Phase I clinical study testing the safety and immunogenicity of its lead infectious disease candidate for genital herpes, ImmunoVEX HSV2. ImmunoVEX HSV2 is a novel live-attenuated...

2008-08-06 09:01:05

Inhibitex, Inc. (NASDAQ: INHX), a biopharmaceutical company focused on the development of products to treat serious infectious diseases, announced today that it has completed a Phase I single ascending dose (SAD) clinical trial and initiated a multiple ascending dose (MAD) trial of FV-100, a highly potent and fast-acting compound being developed to treat shingles (herpes zoster). The double-blind, placebo-controlled SAD trial evaluated the safety and pharmacokinetics of four doses of...


Latest Herpes zoster Reference Libraries

69_7b87211f9314eacab994d465558a3a1b
2011-01-24 12:56:26

Herpes zoster (or zoster), is known as shingles or zona and is a viral disease characterized by painful skin rash with blisters in a limited area on one side of the body. Initial infection causes chickenpox. Once chickenpox is over the virus remains in the body and can cause shingles. It can become latent in the nerve cell bodies and sometimes in the dorsal root, cranial nerve, or autonomic ganglion. Years after initial infection, another breakout can cause a painful rash. The rash usually...

More Articles (1 articles) »